Cargando…

CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) treatment represents a major challenge in oncology. TNBC evolves into chemotherapy resistance for 60 to 70% of the patients. About 77% of the TNBC displays a lack of claudin-1 (CLDN1), a major tight junction component. We demonstrated that CLDN1 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemesle, Marine, Geoffroy, Marine, Alpy, Fabien, Tomasetto, Catherine-Laure, Kuntz, Sandra, Grillier-Vuissoz, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599637/ https://www.ncbi.nlm.nih.gov/pubmed/36291810 http://dx.doi.org/10.3390/cancers14205026

Ejemplares similares

AB186 Inhibits Migration of Triple-Negative Breast Cancer Cells and Interacts with α-Tubulin
por: Geoffroy, Marine, et al.
Publicado: (2022)

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer
por: Ma, Fei, et al.
Publicado: (2014)

Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients
por: Hu, Aimin, et al.
Publicado: (2019)

STARD3: A New Biomarker in HER2-Positive Breast Cancer
por: Lodi, Massimo, et al.
Publicado: (2023)

The phosphoinositide-binding protein TRAF4 modulates tight junction stability and migration of cancer cells
por: Rousseau, Adrien, et al.
Publicado: (2014)

Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
por: C, Ahammad Sameer, et al.
Publicado: (2023)

Tumor Necrosis Factor Receptor-Associated Factor 4 Is a Dynamic Tight Junction-Related Shuttle Protein Involved in Epithelium Homeostasis
por: Kédinger, Valérie, et al.
Publicado: (2008)

Correction: Tumor Necrosis Factor Receptor-Associated Factor 4 Is a Dynamic Tight Junction-Related Shuttle Protein Involved in Epithelium Homeostasis
por: Kédinger, Valérie, et al.
Publicado: (2008)

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line
por: Chamaraux-Tran, Thiên-Nga, et al.
Publicado: (2022)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

STARD3 mediates endoplasmic reticulum‐to‐endosome cholesterol transport at membrane contact sites
por: Wilhelm, Léa P, et al.
Publicado: (2017)

In situ artificial contact sites (ISACS) between synthetic and endogenous organelle membranes allow for quantification of protein-tethering activities
por: Milanini, Julie, et al.
Publicado: (2022)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy
por: Winter, Marie, et al.
Publicado: (2023)

TRAF4 Is a Novel Phosphoinositide-Binding Protein Modulating Tight Junctions and Favoring Cell Migration
por: Rousseau, Adrien, et al.
Publicado: (2013)

The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer
por: Zhang, Guojing, et al.
Publicado: (2021)

Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
por: Zhang, Shuang, et al.
Publicado: (2022)

Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy
por: Wei, Lanjing, et al.
Publicado: (2023)

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
por: Kwon, Mi Jeong, et al.
Publicado: (2010)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer
por: He, Jinsong, et al.
Publicado: (2011)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
por: Anurag, Meenakshi, et al.
Publicado: (2022)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bpi391uqbpfeu3biuqc16rdaqf